Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression.
5-HT receptor genes
antidepressant
polymorphism
treatment response
treatment-free depression
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
09
2019
accepted:
13
11
2019
entrez:
21
1
2020
pubmed:
21
1
2020
medline:
21
1
2020
Statut:
epublish
Résumé
Major depressive disorder has become a prominent cause of disability, as lifetime prevalence has increased to ~15% in the Western world. Pharmacological effects of serotonin (5-hydroxytryptamine, 5-HT) are mediated through 5-hydroxytryptamine receptor (5-HTR) binding. Serotonin regulation of amygdala activity is attained through activation of three 5-HT2 family receptor subtypes, 5-HT2A, 5-HT2B, and 5-HT2C. Specifically, HT2A and the HT2C receptors have similar gross cerebral distribution and function, with higher constitutive activity found in HT2C than in HT2A. We investigated the possible association of 5-HTR gene polymorphisms to specific and non-specific antidepressant treatment responses in treatment-free patients in Siberia. 156 patients, aged between 18-70 years and clinically diagnosed with depressive disorders, were treated with antidepressants for 4 weeks. Patients were genotyped for a subset of 29 SNPs from the following 5-HT Receptor genes: HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B and HTR6. Primary outcome was measured by differences in Hamilton Depression Rating Scale (ΔHAM-D 17) scores between baseline/week two, week two/week four and baseline/week four. Univariate linear regression was initially conducted to determine the 5-HTR SNPs to be studied within the multiple linear regression. Multiple linear regression analyses over the three time periods were conducted for ΔHAM-D 17 with independent factors including: age, gender, depression diagnosis, antidepressant treatment and selected 5-HTR SNPs. We found improved ∆HAM-D 17 in patients taking tricyclic antidepressants (0-4 weeks: B = 4.85, p = 0.0002; 0-2 weeks: B = 3.58, p = 0.002) compared to patients taking SSRIs. Over the course of study, significant associations between 5-HT receptors SNPs and antidepressant response were not identified.
Identifiants
pubmed: 31956308
doi: 10.3389/fphar.2019.01462
pmc: PMC6951408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1462Informations de copyright
Copyright © 2019 Ochi, Vyalova, Losenkov, Paderina, Pozhidaev, Loonen, Simutkin, Bokhan, Ivanova and Wilffert.
Références
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
World J Biol Psychiatry. 2017 Apr;18(3):239-246
pubmed: 27654063
Pharmacogenomics. 2019 Nov;20(17):1199-1223
pubmed: 31686592
Pharmacol Ther. 2018 Jan;181:143-155
pubmed: 28757154
Pharmacol Rev. 2007 Dec;59(4):360-417
pubmed: 18160701
Br J Pharmacol. 2014 Aug;171(15):3604-19
pubmed: 24724693
Am J Med Genet B Neuropsychiatr Genet. 2004 Apr 1;126B(1):124-7
pubmed: 15048662
World J Biol Psychiatry. 2011 Mar;12(2):81-8
pubmed: 21348783
Lancet Psychiatry. 2017 Feb;4(2):146-158
pubmed: 27856392
J Clin Psychiatry. 1999;60 Suppl 4:4-11; discussion 12-3
pubmed: 10086478
Br J Clin Pharmacol. 2014 Apr;77(4):654-72
pubmed: 24354796
World J Biol Psychiatry. 2013 Jul;14(5):334-85
pubmed: 23879318
Neuropsychobiology. 2017;75(4):200-210
pubmed: 29621775
Curr Top Med Chem. 2006;6(18):1971-85
pubmed: 17017968
World J Biol Psychiatry. 2015 Feb;16(2):76-95
pubmed: 25677972
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Clin Pharmacol Biopharm. 2013 Jun 29;2(2):110
pubmed: 24772381
Front Pharmacol. 2014 Apr 09;5:68
pubmed: 24782772
Trends Pharmacol Sci. 2013 Oct;34(10):560-70
pubmed: 24041919
Front Hum Neurosci. 2016 Nov 10;10:571
pubmed: 27891086
Int J Dev Neurosci. 2001 Jul;19(4):365-72
pubmed: 11378296
Nature. 1997 May 15;387(6630):303-8
pubmed: 9153397
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Apr 3;66:120-35
pubmed: 26739950
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):11-26
pubmed: 14965241
J Affect Disord. 2019 Dec 1;259:432-439
pubmed: 31611000
Stat Med. 1984 Apr-Jun;3(2):143-52
pubmed: 6463451
Mol Brain. 2017 Jun 24;10(1):28
pubmed: 28646910
Life Sci. 2003 Apr 18;72(22):2429-49
pubmed: 12650852